Effectiveness and Tolerability of Vortioxetine in Major Depressive Disorder: A Real-World Study in Switzerland

Clinical Drug Investigation · Published 2026-03-15 · DOI 10.1007/s40261-026-01537-z

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s40261-026-01537-z

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Clinical Benefit of Multiple Myeloma Drugs at Regulatory Approval in Brazil, Europe, and the USA: A Retrospective Cohort Study (2003–2024) · Clinical Drug Investigation · 2026 · Same journal
• Desvenlafaxine as a Potential First-Line Treatment for Major Depressive Disorder: A Comprehensive Review and Consensus-Based Clinical Perspective on Efficacy, Safety and Patient Selection Profiles · Clinical Drug Investigation · 2026 · Same journal
• Determinants and Prognostic Impact of In-Hospital Sodium-Glucose Cotransporter-2 Inhibitor Initiation in Patients with Heart Failure · Clinical Drug Investigation · 2026 · Same journal
• Missed Opportunities in the Therapeutic Patterns of Chronic Obstructive Pulmonary Disease: A Real-World Italian Study on the Impact of Severe Exacerbation on Mortality and Hospital Re-admission · Clinical Drug Investigation · 2026 · Same journal
• Milsaperidone: First Approval · Clinical Drug Investigation · 2026 · Same journal
• Cost-Consequences Analysis of Biologic Treatments for Moderate-to-Severe Crohn’s Disease Using Real-World Transition Probability and Cost Data in Thailand · Clinical Drug Investigation · 2026 · Same journal
• Amyloid-Related Imaging Abnormalities in Anti-amyloid Therapy: Clinical Implications of Kinetics for Safer Use and Risk Stratification · Clinical Drug Investigation · 2026 · Same journal
• Over-the-Counter Product Use Among Individuals with Vitiligo: A Cross-Sectional International Survey · Clinical Drug Investigation · 2026 · Same journal
• Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective Disorder · Clinical Drug Investigation · 2026 · Same journal
• A Single-Center, Randomized, Open-Label, Two-Formulation, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of Two Eltrombopag Olamine Tablets (25 mg) in Healthy Chinese Subjects in the Fed State · Clinical Drug Investigation · 2026 · Same journal